Amjevita, the first biosimilar competition for Humira in the United States. At least seven others are expected to debut this summer.
Overall, Humira sales rose 4.6% to $5.58 billion, in line with estimates, lifted by growth in the U.S. market. Skyrizi sales of $1.58 billion beat analysts' estimates of $1.52 billion, while Rinvoq missed with $770 million in sales compared with expectations of $816.14 million.